~~<i id='AE39C6AB4A'><strike id='AE39C6AB4A'><tt id='AE39C6AB4A'><pre id='AE39C6AB4A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

author：focus 2025-09-29 01:37:42 - browse：3642

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Young boy dies in trial for Pfizer Duchenne gene therapy

entertainment

leisure time

Wikipedia

knowledge

leisure time

explore

Thestudyofeugenicswasn’tbornonLongIsland—it’sclosertosayitwentthroughpubertythere.Theideaofeugenics—

WSS

Study finds new variant for Parkinson’s in African populations

Australia’s approach to dialysis celebrates life

Psilocybin's anti

Researchers test human milk's ability to repair gut microbiome

Diversity in medical illustrations gets boost from Chidiebere Ibe

UnitedHealth, in a surprise, takes aim at Steward’s physician group

leisure time

leisure time

entertainment

Medicare details structure of new drug price negotiation program

Medicare Advantage 2025 payments will dip, Biden administration says

Psychedelics group wrestles with new pharma identity

2024 GOP presidential candidates spar over abortion in debate

How to save PrEP access — and even expand it

Insurer loopholes limit power of law against surprise medical bills

Continuity nursing helped my family in our darkest PICU moments

AstraZeneca bets AAV gene therapy will still deliver the goods

Supreme Court strikes down use of affirmative action

As pharma fights Medicare drug negotiation, hospitals, docs silent

leisure time

Insurer loopholes limit power of law against surprise medical bills

AstraZeneca challenges Medicare drug negotiation program

What do new weight loss drugs mean for bariatric surgery?

Overprescribed: High cost isn't America's only drug problem

AstraZeneca challenges Medicare drug negotiation program

Four alarming medical procedures we’re glad history forgot

Wikipedia

knowledge

leisure time

explore